Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticlePsoriatic Arthritis

Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort

Ennio Lubrano, Antonia De Socio and Fabio Massimo Perrotta
The Journal of Rheumatology August 2017, 44 (8) 1159-1164; DOI: https://doi.org/10.3899/jrheum.170112
Ennio Lubrano
From the Dipartimento di Medicina e Scienze della Salute Vincenzo Tiberio, Università degli Studi del Molise, Campobasso, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: enniolubrano@hotmail.com
Antonia De Socio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabio Massimo Perrotta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

REFERENCES

  1. 1.↵
    1. Gladman DD,
    2. Antoni C,
    3. Mease P,
    4. Clegg DO,
    5. Nash P
    . Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64 Suppl 2:ii14–7.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. McHugh NJ,
    2. Balachrishnan C,
    3. Jones SM
    . Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 2003;42:778–83.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Gordon GB,
    2. Ruderman E
    1. Gladman DD
    . Disability and quality of life considerations. Psoriatic arthritis. In: Gordon GB, Ruderman E, eds. Psoriasis and psoriatic arthritis: an integral approach. Heidelberg: Springer-Verlag; 2005:118–237.
  4. 4.↵
    1. Helliwell P,
    2. Coates L,
    3. Chandran V,
    4. Gladman D,
    5. de Wit M,
    6. FitzGerald O,
    7. et al.
    Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res 2014;66:1759–66.
    OpenUrlCrossRef
  5. 5.↵
    1. Perrotta FM,
    2. Lubrano E
    . Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study. Postgrad Med 2016;128:693–6.
    OpenUrl
  6. 6.↵
    1. Ash Z,
    2. Gaujoux-Viala C,
    3. Gossec L,
    4. Hensor EM,
    5. FitzGerald O,
    6. Winthrop K,
    7. et al.
    A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71:319–26.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Glintborg B,
    2. Østergaard M,
    3. Dreyer L,
    4. Krogh NS,
    5. Tarp U,
    6. Hansen MS,
    7. et al.
    Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011;63:382–90.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Perrotta FM,
    2. Marchesoni A,
    3. Lubrano E
    . Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J Rheumatol 2016;43:350–5.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Lubrano E,
    2. Parsons WJ,
    3. Perrotta FM
    . Assessment of response to treatment, remission, and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors. J Rheumatol 2016;43:918–23.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Lubrano E,
    2. Perrotta FM
    . Secukinumab for ankylosing spondylitis and psoriatic arthritis. Ther Clin Risk Manag 2016;12:1587–92.
    OpenUrl
  11. 11.↵
    1. Perrotta FM,
    2. Lubrano E
    . New approved drugs for psoriatic arthritis. Reumatismo 2016;68:57–64.
    OpenUrl
  12. 12.↵
    1. Lubrano E,
    2. Perrotta FM
    . Beyond TNF inhibitors: new pathways and emerging treatments for psoriatic arthritis. Drugs 2016;76:663–73.
    OpenUrl
  13. 13.↵
    1. Coates LC,
    2. Kavanaugh A,
    3. Mease PJ,
    4. Soriano ER,
    5. Laura Acosta-Felquer M,
    6. Armstrong AW,
    7. et al.
    Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 2016;68:1060–71.
    OpenUrl
  14. 14.↵
    1. Gossec L,
    2. Smolen JS,
    3. Ramiro S,
    4. de Wit M,
    5. Cutolo M,
    6. Dougados M,
    7. et al.
    European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499–510.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Lubrano E,
    2. Soriano E,
    3. FitzGerald O
    . Can traditional disease-modifying anti-rheumatic drugs be withdrawn or tapered in psoriatic arthritis? Clin Exp Rheumatol 2013;31 Suppl 78:S54–8
    OpenUrlPubMed
  16. 16.↵
    1. Lubrano E,
    2. Perrotta FM,
    3. Kavanaugh A
    . An overview of low disease activity and remission in psoriatic arthritis. Clin Exp Rheumatol 2015;33 Suppl 93:51–4.
    OpenUrl
  17. 17.↵
    1. Coates LC,
    2. Fransen J,
    3. Helliwell PS
    . Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69:48–53.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Coates L,
    2. Helliwell P
    . Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Car Res 2010;62;965–9.
    OpenUrl
  19. 19.↵
    1. Coates LC,
    2. Helliwell PS
    . Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol 2016;43:371–5.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Helliwell PS,
    2. FitzGerald O,
    3. Fransen J,
    4. Gladman DD,
    5. Kreuger GG,
    6. Callis-Duffin K,
    7. et al.
    The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013;72:986–91.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Helliwell PS,
    2. FitzGerald O,
    3. Fransen J
    . Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol 2014;41:1212–7.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Schoels MM,
    2. Aletaha D,
    3. Alasti F,
    4. Smolen JS
    . Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 2016;75:811–8.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Soriano ER
    . The actual role of therapy with traditional disease-modifying antirheumatic drugs in psoriatic arthritis. J Rheumatol 2012;89:67–70.
    OpenUrl
  24. 24.↵
    1. Taylor W,
    2. Gladman D,
    3. Helliwell P,
    4. Marchesoni A,
    5. Mease P,
    6. Mielants H;
    7. CASPAR Study Group
    . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Healy PJ,
    2. Helliwell PS
    . Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008;59:686–91.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Chandran V,
    2. Gottlieb A,
    3. Cook RJ,
    4. Duffin KC,
    5. Garg A,
    6. Helliwell P,
    7. et al.
    International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis Rheum 2009;61:1235–42.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Ranza R,
    2. Marchesoni A,
    3. Calori G,
    4. Bianchi G,
    5. Braga M,
    6. Canazza S,
    7. et al.
    The Italian version of the Functional Disability Index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol 1993;11:123–8.
    OpenUrlPubMed
  28. 28.↵
    1. Ware JE Jr,
    2. Sherbourne CD
    . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Cauli A,
    2. Gladman DD,
    3. Mathieu A,
    4. Olivieri I,
    5. Porru G,
    6. Tak PP,
    7. et al;
    8. GRAPPA 3PPsA Study Group
    . Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol 2011;38:898–903.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Nell-Duxneuner VP,
    2. Stamm TA,
    3. Machold KP,
    4. Pflugbeil S,
    5. Aletaha D,
    6. Smolen JS
    . Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis 2010;69:546–9.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Lubrano E,
    2. Perrotta FM,
    3. Marchesoni A,
    4. D’Angelo S,
    5. Ramonda R,
    6. Addimanda O,
    7. et al.
    Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study. J Rheumatol 2015;42:258–63.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Spadaro A,
    2. Lubrano E,
    3. Marchesoni A,
    4. D’Angelo S,
    5. Ramonda R,
    6. Addimanda O,
    7. et al.
    Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. Rheumatology 2013;52:1914–9.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Haddad A,
    2. Thavaneswaran A,
    3. Ruiz-Arruza I,
    4. Pellett F,
    5. Chandran V,
    6. Cook RJ,
    7. et al.
    Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis. Arthritis Care Res 2015;67:842–7.
    OpenUrlCrossRef
  34. 34.↵
    1. Coates LC,
    2. Helliwell PS
    . Methotrexate efficacy in the tight control in psoriatic arthritis study. J Rheumatol 2016;43:356–61.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Sheane BJ,
    2. Thavaneswaran A,
    3. Gladman DD,
    4. Chandran V
    . Attainment of minimal disease activity using methotrexate in psoriatic arthritis. J Rheumatol 2016;43:1718–23.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 44, Issue 8
1 Aug 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort
Ennio Lubrano, Antonia De Socio, Fabio Massimo Perrotta
The Journal of Rheumatology Aug 2017, 44 (8) 1159-1164; DOI: 10.3899/jrheum.170112

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort
Ennio Lubrano, Antonia De Socio, Fabio Massimo Perrotta
The Journal of Rheumatology Aug 2017, 44 (8) 1159-1164; DOI: 10.3899/jrheum.170112
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Keywords

PSORIATIC ARTHRITIS
REMISSION
COMPOSITE INDICES
BIOLOGIC THERAPY
DMARD

Related Articles

Cited By...

More in this TOC Section

  • Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study
  • Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial
  • Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Show more Psoriatic Arthritis

Similar Articles

Keywords

  • psoriatic arthritis
  • remission
  • composite indices
  • biologic therapy
  • DMARD

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire